Nick.jpg

​Clinical Assistant Professor

BA (Wesleyan University, MBChB (CUHK), MRCS (Edinburgh) FCOphthHK, FHKAM (Ophthalmology)   

Phone: 2518 1430 / 3962 1405
Email: nfung@hku.hk

ORCID: 0000-0001-7181-0834

Dr. Nicholas Fung graduated from Wesleyan University (BA) followed by graduate studies at Harvard University before returning to Hong Kong for his medical studies (MBChB) at the Chinese University of Hong Kong in 2000. He has been working in ophthalmology at Queen Mary Hospital and Grantham Hospital since 2008.  Apart from general ophthalmology, his focus in ophthalmology is in vitreoretinal diseases and surgery. 

Dr Fung’s research areas in medical retina, include landmark International collaboration studies on age related macular degeneration, diabetic maculopathy, retinal vascular diseases, and polypoidal chorioretinopathy, bringing multiple anti VEGF treatments into Hong Kong.  His research in surgical retina include retinal detachment and macular diseases from macular hole to epiretinal membranes.  After joining HKU as a clinical assistant professor, he continues to promote and deliver his research around the world at various International and Regional ophthalmology conferences as well as on local Hong Kong media.  His surgical interests have also led to the introduction of the first digital microscope into Hong Kong and SE Asia in 2020.

Dr Fung’s recent work with teaching in HKU also lead to the introduction of virtual reality and simulation into the medical students’ curriculum.

.

Memberships & Posts

  • American Academy of Ophthalmology (member# 888844)

  • American Society of Retina Specialists (member# 714131)

  • Asia Pacific Ophthalmic Trauma Society (member# APOTS_0083)

  • Clinical Assistant Professor (The University of Hong Kong, Since Jan 2019)

  • Adjunct Assistant Professor (The Hong Kong Polytechnic University), Since Jan 2019)

  • Consultant, Hong Kong University Shenzhen Hospital (Since Jan 2019)

  • Hospital Authority, Queen Mary Hospital & Grantham Hospital (Since July 2008)

Active on going research

Age Related Macular Degeneration 黃斑病變:

  • Principal Investigator in International multicenter Clinical trials:

    • Avonelle-X (X/GR42691): A Multicenter, open-label extension study to evaluate the long term safety and tolerability of Faricimab in patients with Neovascular age-related macular degeneration - (Sponsored by Roche Holding AG)

    • AMGEN (20170542): A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration - (Sponsored by AMGEN Inc)

    • Everest & Planet follow up study: To determine long-term outcomes, recurrence rates, and treatment needs in PCV - (in collaboration with Singapore Eye Research Institute)

    • LUCERNE (40844): A phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety of Faricimab in patients with neovascular age-related macular degeneration - (Sponsored by Roche Holding AG)

    • PANDA: A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-related Macular Degeneration - (Sponsored by Chengdu Kanghong Pharmaceuticals)

    • CEDAR/SEQUOIA: Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration - completed 2019 (Sponsored by Allergan)

    • PLANET: A randomized, double-masked, sham-controlled phase 3b/4 study of the efficacy, safety, and tolerability of intravitreal aflibercept monotherapy compared to aflibercept with adjunctive photodynamic therapy as indicated in subjects with polypoidal choroidal vasculopathy (Aflibercept) - completed 2018 (Sponsored by Bayer AG)

    • EVEREST2: A 24-month, phase IV, randomized, double masked, multicenter study of ranibizumab monotherapy or ranibizumab in combination with verteporfin photodynamic therapy on visual outcome in patients with symptomatic macular polypoidal choroidal vasculopathy - completed 2017 (Sponsored by Novartis International AG)

Diabetic Macular diseases 糖尿上眼:

  • Principal Investigator in International multicenter Clinical trials:

    • RHINE (GR40398): A phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety of RO6867461in patients with diabetic macular edema - (Roche Holding AG)

    • RHONE X: (GR41987) A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients with Diabetic Macular Edema - (Sponsored by Roche Holding AG)

    • VIVID East: A randomized, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macular edema - completed 2016 (Sponsored by Bayer AG)

Retinal Vein Occludion 視網膜血管閉塞:

  • Principal Investigator in International multicenter Clinical trials:

    • Balaton (GR41984) A phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety of Faricimab in patients with macular edema secondary to branch retinal vein occlusion - (Sponsored by Roche Holding AG)

    • Comino (GR41986) A phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety of Faricimab in patients with macular edema secondary to central retinal or hemiretinal vein occlusion - (Sponsored by Roche Holding AG)

Other on going research as Principal Investigator:

  • Development and Introduction of 3D digital ophthalmic microsurgery

  • Virtual Reality and Simulator teaching of medical students at the University of Hong Kong

  • Intraocular Lens stability after combined cataract and vitreoretinal surgery

  • Glaucoma in patients undergoing intraocular injections of anti VEGF for macular diseases

  • Myopia epidemiology related to retinal and macular degeneration

Retinopathy of Prematurity 早產兒視網膜病變:

  • Co-Investigator in International multicenter Clinical trials:

    • FireFleye Next: Protocol 20275 - An extension study to evaluate the long-term outcomes of subjects who received treatment for retinopathy of prematurity in Study 20090 - (Alfibercept) (Sponsored by Bayer AG)

    • FireFleye: A randomized, two-arm, phase 3 study to evaluate and compare the efficacy, safety and tolerability of intravitreal aflibercept versus laser photocoagulation for the treatment of retinopathy of prematurity - (Aflibercept) (Sponsored by Bayer AG Bayer)

ACADEMIC PRESENTATIONS

  • WOC 2020: Invited speaker - Trauma Symposium “How to Make the Vitreo-retinal Surgeon's Life Easier in Open Globe Injuries”

  • ASM 2019: Invited speaker - HKU symposium & GBO symposium “juvenile retinoschisis”

  • KRS 2019: Invited speaker - Update on Faricimab phase 2 trial results

  • APVRS 2019: Poster presentation for “Retinal layer characteristics on SD-OCT as predictors of post-operative visual outcome in idiopathic epiretinal membrane surgery”

  • Euretina 2019: First Author poster presentation for “A series of ILM transposition for chronic and persistent macula hole by tuck technique” & Surgical video competition “Double needle flange technique for a subluxed IOL in a silicone oil filled giant tear retinal detachment” - placed 3rd for conference popularity

  • ARVO 2019: Co Author poster presentation for “Efficacy of an endocrinologist led specialist care clinic in minimising burden of vision threatening retinopathy in Chinese diabetics”

  • APAO 2019: First Author poster presentation for “Series of ILM Transposition in large, chronic full thickness macula hole”

  • APVRS 2018: Speaker for “ILM Transposition for Chronic full thickness macula hole with previously failed vitrectomy” & “Using OCT to assist in diagnosis and monitor treatment response of ocular lymphoma”

  • Euretina 2018: Speaker / Presenter for “Using OCT to Monitor the treatment of PCNSL with intravitreal Methotrexate”

  • APAO 2018: Invited Speaker in Retina Surgical video case conference - Modified Double needle scleral fixated IOL by flanged technique

  • Euretina 2016: First Author Poster presentation - "To evaluate the effectiveness of the current Hong Kong diabetic maculopathy screening using optical coherence tomography (OCT) scan as reference standard”, “Relationship between outer retinal layers thicknesses and visual acuity in patients with diabetic macular edema”, "A prospective study on morphological features of diabetic maculopathy in relation to patient characteristics”

  • AAO 2014: First Author Poster presentation - Clamp Assisted retractor advancement for lower eyelid involutional entropion

  • WOC 2014: Instruction Course presenter - Polypoidal Choroidal Vasculopathy

  • WGC 2013: First Author Poster presentation - Changes in IOP and CCT before, throughout and after hemodialysis

  • APVRS 2013: First Author Poster presentation - Efficacy of single dose of Ranibizumab in patients with diabetic macular oedema

Awards

  1. 2019 Recipient of Outstanding team award for Grantham Hospital, Hospital Authority, as the Team Leader for his work in treatment of Age related macular degeneration and Diabetic Macular Edema through introduction of Treat & Extend of intravitreal anti VEGF drugs

  2. 2020 Recipient of Outstanding team award in West Cluster, Hospital Authority, as the Team Leader for his work in treatment of Age related macular degeneration and Diabetic Macular Edema through introduction the of Treat & Extend of intravitreal anti VEGF drugs

Published Papers

  1. Danny S. C. Ng, Nicholas S. K. Fung, Fanny L. T. Yip & Timothy Y.Y. Lai (2020) Ranibizumab for myopic choroidal neovascularization, Expert Opinion on Biological Therapy, DOI: 10.1080/14712598.2021.1830969 (Impact Factor: 3.947)

  2. Chow, L.W.L., Fung, N.S.K. & Kwok, K.H.A. Premium intraocular lens implantation in eyes with vitrectomy done. Int Ophthalmol (2020). https://doi.org/10.1007/s10792-020-01478-2

  3. Fung NS, Mak A, Yiu R, Lam WC. Treatment of large, chronic and persistent macular hole with internal limiting membrane transposition and tuck technique, International Journal of Retina and VItreous. DOI : 10.1186/s40942-019-0206-7, IJRV-D-19-00062R1 (3.190 CiteScore)

  4. Wong IY, Fung NS, Timothy YY Lai et al. Treat and extend regimen for management of Neovascular age related macular degeneration: recommendations from the Hong Kong Retina Expert Panel. HKJOphthalmology (2019) Vol 23, No1, 15-19, DOI: 12809/hkjo-v23nl-T&E

  5. Wong IY, Shi X, Gangwani R, Iu LP, Fung NS, Li Q, Ng AL, Li XX. 1-year results of half versus standard dose photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy. Retina (2018) 38(4) 725-730, DOI: 10.1097/IAE.0000000000001614. (Impact factor 3.039, ranked 9/56 in Ophthalmology)

  6. Iu LP, Zhao P, Yeung IY, Fung NS, Lee JW, Wong RL, Chong, V, Wong IY. Sequential therapy with ranibizumab and dexamethasone intravitreal implant is better than dexamethasone monotherapy for macular oedema due to retinal vein occlusion. Br J Ophthalmol, 2014 Feb;99(2):210-4. (Impact factor 3.036, ranked 10/56 in Ophthalmology)

  7. Ma KK, Chau WW, Wong CH, Wong K, Fung NS, Lee AJ, Choi CL, Suen DT, Kwong A. Triple negative status is a poor prognostic indicator in Chinese women with breast cancer: a ten year review.  Asian Pac J Cancer Prev. 2012;13(5):2109-14. PMID: 22901178 (Impact factor 2.52)

  8. Li H, Louey JW, Choy KW, Liu DT, Chan WM, Chan YM, Fung NS, Fan BJ, Baum L, Chan JC, Lam DS, Pang CP. EDN1 Lys198Asn is associated with diabetic retinopathy in type 2 diabetes: Mol Vis 2008 Sep 15; 14:1698-704, PMID 18806884

  9. Seamon JG, Goodkind MS, Dumey AD, Dick E, Aufseeser MS, Strickland SE, Woulfin JR, Fung NS. Effects of encoding attention and practice on accurate and false memory: Mem Cognit 2003 Apr 31 (3):  445-57, PMID 12795486 (Impact factor 2.457)

  10. Seamon JG, Luo CR, Kopecky JJ, Price CA, Rothschld L, Fung NS, Schwartz MA. The effect of retention interval on recall and recognition: Mem Cognit 2002 Oct; 30(7): 1054-64, PMID 12507370 (Impact factor 2.457)